Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30701145 | 1.00 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19330204 | 0.88 | ALDH1A1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30701165 | 0.88 | ALDH1A1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL943936 | 0.81 | F2 (0.59) | F2F10CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL19330218 | 0.80 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19353932 | 0.79 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1314039 | 0.79 | GPR119 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21669555 | 0.77 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19330153 | 0.77 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9866873 | 0.76 | CYP1A2 (0.46) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109069514-B | Antibacterial compound and application thereof | 结核病药物开发全球联盟公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4148053-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | The Global Alliance for TB Drug Development, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3426255-B1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3426255-B1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-10981891-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200039955-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10508097-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-10508097-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-20190071417-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20190071417-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-3426255-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | The Global Alliance for TB Drug Development, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017155909-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017155909-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981891-B2 | Antibacterial compounds and uses thereof | CFTR, SQOR, NQO1 | CA12 3630/4885CA1 4614/4885CA2 3658/4885 |
| US-20200039955-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | CFTR, SQOR, NQO1 | CA12 3630/4885CA1 4614/4885CA2 3658/4885 |
| US-10508097-B2 | Antibacterial compounds and uses thereof | CFTR, SQOR, NQO1 | CA12 3630/4885CA1 4614/4885CA2 3658/4885 |
| US-20190071417-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | CFTR, SQOR, NQO1 | CA12 3630/4885CA1 4614/4885CA2 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.